| Literature DB >> 26220091 |
Oxana Trifonova1, Richard A Knight2, Andrey Lisitsa1, Gerry Melino2, Alexey V Antonov3.
Abstract
In many cases, individuality in metabolism of a drug is a reliable predictor of the drug efficacy/safety. Modern high-throughput metabolomics is an ideal instrument to track drug metabolism in an individual after treatment. Productivity and low cost of the metabolomics are sufficient to analyse a large cohort of patients to explore individual variations in drug metabolism and to discover drug metabolic biomarkers indicative of drug efficacy/safety. The only potential disadvantage of metabolomics becoming a routine clinical procedure is a need to treat the patient once before making a prognosis. However, in many clinical applications this would not be a limitation. Here, we explore current opportunities and challenges for translating high-throughput metabolomics into the platform for personalized medicine.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26220091 DOI: 10.1016/j.drudis.2015.07.011
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851